ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage specialty biopharmaceutical company focused on developing treatments for inflammation and rare kidney diseases, with its lead IC 100 inflammasome inhibitor among its core pipeline assets. ZyVersa completed a SPAC business combination in 2022 and began trading on the Nasdaq Capital Market under the ZVSA ticker, operating in the clinical-stage biotechnology sector. The company filed an 8-K with the SEC on April 17, 2024, disclosing a material corporate development following its de-SPAC transition. Analysts and investors tracking ZVSA can sign up on SpacDesk for complete data on the company's filing history, SPAC deal background, and ongoing SEC disclosures.